What is a relative contraindication for DVT prophylaxis?

Relative contraindications for DVT prophylaxis refer to situations where the risks of administering prophylactic treatment may outweigh the benefits, but it may still be considered depending on the specific clinical circumstances.

In this context, the use of low molecular weight heparin (LMWH), while generally safe and effective for DVT prophylaxis, can be a relative contraindication in certain scenarios. For example, patients who have active bleeding or those with a high risk of bleeding may be prescribed LMWH with caution. Further, if a patient has been receiving anticoagulation therapy or has conditions that predispose them to hemorrhage, the risks associated with LMWH administration may necessitate careful consideration and monitoring.

Conversely, the other choices do not represent relative contraindications. Insulin therapy is unrelated to the context of DVT prophylaxis. Uncontrolled hypertension is a more significant contraindication when considering anticoagulation therapies due to an increased risk of bleeding. Oral anticoagulants are a treatment rather than a contraindication for DVT prophylaxis. DVT prophylaxis can often be adjusted based on the patient's ongoing anticoagulation needs, but LMWH must always be approached with caution in specific clinical scenarios.